Home
Goodwin Procter LLP
Yoko J. Bian
Yoko J. Bian
Goodwin Procter LLP
Regeneron Sues Samsung Bioepis For Proposed Biosimilar Of EYLEA In West Virginia District Court
30 Nov 2023 | United States
UK Authorizes World-First Gene Therapy From Vertex And CRISPR Therapeutics For Blood Disorders
22 Nov 2023 | UK
Meitheal Announces Exclusive Commercial Licensing Agreement For Insulin Biosimilars In The US
19 Oct 2023 | United States
Generic And Biosimilar Drugs Save $408B For America's Patients And Healthcare System In 2022
18 Sep 2023 | United States
HUMIRA (adalimumab) Biosimilar Launches
11 Jul 2023 | United States
Updates On Recent Foreign Approvals And Launches
09 Jun 2023 | United States
Alvotech And Advanz Pharma Extend Partnership To Commercialize Five Proposed Biosimilars In Europe
02 Jun 2023 | United States
Bristol-Myers Squibb Files Patent Infringement Complaint Against AstraZeneca Regarding Anti-PD-L1 Antibody Product
04 May 2023 | United States
Purple Book Updates (April 27, 2023)
03 May 2023 | United States
Coya Announces Agreement With Dr. Reddy's Laboratories For Treatment Of Neurodegenerative Diseases
30 Mar 2023 | United States
FDA Issues CRL For Biocon/Viatris Bevacizumab Biosimilar
28 Feb 2023 | United States
Alvotech And Teva Announce Acceptance Of BLA For AVT04, A Proposed Biosimilar To STELARA (Ustekinumab)
20 Jan 2023 | United States
Alvotech Initiates Study Of Biosimilar Of J&J's Rheumatoid Arthritis Drug SIMPONI
17 Jan 2023 | United States
Coherus Agrees To Acquire A Biosimilar EYLEA Candidate From Klinge Biopharma
17 Jan 2023 | United States
Year In Review: Top Deals In 2022
11 Jan 2023 | United States
Alvotech Broadens Access To HUMIRA (Adalimumab) Biosimilars
14 Dec 2022 | United States
AbbVie's Q322 Earnings Call Highlights Oncoming Adalimumab Biosimilar Competition
07 Nov 2022 | United States
EMA Adopts Positive Opinion For STADA And Xbrane's Ranibuzumab Biosimilar Candidate XIMLUCI®
30 Sep 2022 | United States
Biosimilar Regulatory Approval Updates
30 Aug 2022 | United States
Alvotech Initiates Confirmatory Patient Study For AVT03, A Proposed Denosumab Biosimilar
29 Aug 2022 | United States
< 1 2 >
Contact Details
New York
Email Website
The New York Times Building
620 Eighth Avenue
New York NY 10018
United States
Telephone: 1-212-4597265

  © Mondaq® Ltd 1994 - 2023. All Rights Reserved.